BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 34719426)

  • 1. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
    Kfoury Y; Baryawno N; Severe N; Mei S; Gustafsson K; Hirz T; Brouse T; Scadden EW; Igolkina AA; Kokkaliaris K; Choi BD; Barkas N; Randolph MA; Shin JH; Saylor PJ; Scadden DT; Sykes DB; Kharchenko PV;
    Cancer Cell; 2021 Nov; 39(11):1464-1478.e8. PubMed ID: 34719426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer.
    Ghadjar P; Loddenkemper C; Coupland SE; Stroux A; Noutsias M; Thiel E; Christoph F; Miller K; Scheibenbogen C; Keilholz U
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1181-9. PubMed ID: 18465142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating the immune microenvironment of prostate cancer induced bone disease.
    Ihle CL; Owens P
    Mol Carcinog; 2020 Jul; 59(7):822-829. PubMed ID: 32233011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment.
    Liu Y; Wei D; Deguchi Y; Xu W; Tian R; Liu F; Xu M; Mao F; Li D; Chen W; Valentin LA; Deguchi E; Yao JC; Shureiqi I; Zuo X
    Gastric Cancer; 2023 Nov; 26(6):904-917. PubMed ID: 37572185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling.
    Xie T; Fu DJ; Li ZM; Lv DJ; Song XL; Yu YZ; Wang C; Li KJ; Zhai B; Wu J; Feng NH; Zhao SC
    Mol Cancer; 2022 Sep; 21(1):173. PubMed ID: 36045408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL20/CCR6 expression profile in pancreatic cancer.
    Rubie C; Frick VO; Ghadjar P; Wagner M; Grimm H; Vicinus B; Justinger C; Graeber S; Schilling MK
    J Transl Med; 2010 May; 8():45. PubMed ID: 20459729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
    Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
    Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived CCL20 affects B16 melanoma growth in mice.
    Martin-Garcia D; Silva-Vilches C; Will R; Enk AH; Lonsdorf AS
    J Dermatol Sci; 2020 Jan; 97(1):57-65. PubMed ID: 31883833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response.
    Bouchet M; Lainé A; Boyault C; Proponnet-Guerault M; Meugnier E; Bouazza L; Kan CWS; Geraci S; El-Moghrabi S; Hernandez-Vargas H; Benetollo C; Yoshiko Y; Duterque-Coquillaud M; Clézardin P; Marie JC; Bonnelye E
    Cancer Res; 2020 Jul; 80(13):2914-2926. PubMed ID: 32366476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer.
    Yin C; Wang M; Wang Y; Lin Q; Lin K; Du H; Lang C; Dai Y; Peng X
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36941015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20-CCR6 axis.
    Kano H; Izumi K; Hiratsuka K; Toriumi R; Nakagawa R; Aoyama S; Kamijima T; Shimada T; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Saito Y; Nakagawa-Goto K; Yoshioka K; Nakata H; Lin WJ; Mizokami A
    Cancer Sci; 2023 Apr; 114(4):1479-1490. PubMed ID: 36479732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended?
    Lee AY; Phan TK; Hulett MD; Körner H
    Cytokine; 2015 Mar; 72(1):97-101. PubMed ID: 25585877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
    Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway.
    Lu E; Su J; Zhou Y; Zhang C; Wang Y
    Biomed Pharmacother; 2017 Jan; 85():486-492. PubMed ID: 27916417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
    Ito M; Teshima K; Ikeda S; Kitadate A; Watanabe A; Nara M; Yamashita J; Ohshima K; Sawada K; Tagawa H
    Blood; 2014 Mar; 123(10):1499-511. PubMed ID: 24385540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma.
    Du D; Liu Y; Qian H; Zhang B; Tang X; Zhang T; Liu W
    Int J Mol Sci; 2014 Apr; 15(4):6441-52. PubMed ID: 24743888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL20/CCR6 Signaling Regulates Bone Mass Accrual in Mice.
    Doucet M; Jayaraman S; Swenson E; Tusing B; Weber KL; Kominsky SL
    J Bone Miner Res; 2016 Jul; 31(7):1381-90. PubMed ID: 26890063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.
    Roca H; Jones JD; Purica MC; Weidner S; Koh AJ; Kuo R; Wilkinson JE; Wang Y; Daignault-Newton S; Pienta KJ; Morgan TM; Keller ET; Nör JE; Shea LD; McCauley LK
    J Clin Invest; 2018 Jan; 128(1):248-266. PubMed ID: 29202471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ expression of the CCL20-CCR6 axis in lymphocyte-rich gastric cancer and its potential role in the formation of lymphoid stroma.
    Ohtani H; Nakayama T; Yoshie O
    Pathol Int; 2011 Nov; 61(11):645-51. PubMed ID: 22029675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.